Relative Bioavailability of a BI 1467335 Tablet Compared to a BI 1467335 Oral Solution and the Effect of Food on the Bioavailability of the Tablet Following Oral Administration (a Randomised, Open-label, Single Dose, Three-way Crossover Trial in Healthy Male Subjects)
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2017
At a glance
- Drugs BI 1467335 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 18 Apr 2017 Status changed from recruiting to completed.
- 21 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
- 21 Feb 2017 Status changed from not yet recruiting to recruiting.